The Zero Person Biotech
Drug Baron
The Needs for 12 Years of Data Protection for Biologics
Biotechnology Industry Organization (BIO)
As tweeted...I do agree with the BIO viewpoint, FWIW.
A Race to Save the Orange by Altering its DNA
Amy Harmon (New York Times)
A much-discussed and excellent long-read piece in the GMO battlegrounds.
Are 90% Of FDA Drugs Approved In Last 30 Years No More Effective Than Existing Drugs?
John LaMattina (Forbes)
FirstWord Lists: FDA approvals since 2000 – Which companies have achieved the highest regulatory success and other key observations
FirstWord Pharma
Pharma Fails Credibility Test, Misses Opportunity, on Transparency
Luke Timmerman (Xconomy)
On the subject of disclosure of clinical trial data (not just the good results...).
Brazen Scofflaws? Are Pharma Companies Really Completely Ignoring FDAAA?
Paul Ivsin (Placebo Control)
Another blog post on the same subject, with comments from Ben Goldacre and...me.
Drug Baron
The Needs for 12 Years of Data Protection for Biologics
Biotechnology Industry Organization (BIO)
As tweeted...I do agree with the BIO viewpoint, FWIW.
A Race to Save the Orange by Altering its DNA
Amy Harmon (New York Times)
A much-discussed and excellent long-read piece in the GMO battlegrounds.
Are 90% Of FDA Drugs Approved In Last 30 Years No More Effective Than Existing Drugs?
John LaMattina (Forbes)
FirstWord Lists: FDA approvals since 2000 – Which companies have achieved the highest regulatory success and other key observations
FirstWord Pharma
Pharma Fails Credibility Test, Misses Opportunity, on Transparency
Luke Timmerman (Xconomy)
On the subject of disclosure of clinical trial data (not just the good results...).
Brazen Scofflaws? Are Pharma Companies Really Completely Ignoring FDAAA?
Paul Ivsin (Placebo Control)
Another blog post on the same subject, with comments from Ben Goldacre and...me.
RSS Feed
